FDA Approved Medical Products for:

Chronic lymphocytic leukemia

The table(s) below may not be an exhaustive list of drugs or products used to treat this condition. There may be other products available that are not considered orphan products.

Generic Name Ofatumumab
Trade Name
(Manufacturer Name)
Arzerra
(GlaxoSmithKline)
Indication
The FDA has approved this product to be used in this manner.
Ofatumumab in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate.
More Information about this product Drug Information Portal

Generic Name Alemtuzumab
Trade Name
(Manufacturer Name)
Campath®
(Genzyme Corporation)
Indication
The FDA has approved this product to be used in this manner.
The treatment of patients with B-cell chronic lymphocytic leukemia who have been treated with alkylating agents and who have failed fludarabine therapy.
More Information about this product Drug Information Portal
Medline Plus Health Information

Generic Name Buffered intrathecal electrolyte/dextrose injection
Trade Name
(Manufacturer Name)
Elliotts B Solution
(QOL Medical, LLC)
Indication
The FDA has approved this product to be used in this manner.
For the intrathecal administration of methotrexate and cytarabine for the prevention or treatment of meningeal leukemia and lymphocytic lymphoma.
More Information about this product Drug Information Portal

Generic Name Fludarabine phosphate
Trade Name
(Manufacturer Name)
Fludara®
(Genzyme)
Indication
The FDA has approved this product to be used in this manner.
Treatment of chronic lymphocytic leukemia (CLL), including refractory CLL.
More Information about this product Drug Information Portal
Medline Plus Health Information

Generic Name Fludarabine phosphate oral tablets
Trade Name
(Manufacturer Name)
Fludarabine® (oral)
(Antisoma )
Indication
The FDA has approved this product to be used in this manner.
Treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) whose disease has not responded to or has progressed during or after treatment with at least one standard alkylating-agent containing regimen
More Information about this product Drug Information Portal

Generic Name obinutuzumab
Trade Name
(Manufacturer Name)
Gazyva
(Genentech, Inc.)
Indication
The FDA has approved this product to be used in this manner.
Treatment of patients with previously untreated chronic lymphocytic leukemia in combination with chlorambucil.
More Information about this product Drug Information Portal

Generic Name ibrutinib
Trade Name
(Manufacturer Name)
Imbruvica
(Pharmacyclics, Inc.)
Indication
The FDA has approved this product to be used in this manner.
Treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy. Treatment of patients with Chronic lymphocytic leukemia with 17p deletion.
More Information about this product Drug Information Portal

Generic Name Bendamustine hydrochloride
Trade Name
(Manufacturer Name)
Treanda
(Cephalon® Oncology)
Indication
The FDA has approved this product to be used in this manner.
Treatment of patients with chronic lymphocytic leukemia
More Information about this product Drug Information Portal
Medline Plus Health Information

Generic Name idelalisib
Trade Name
(Manufacturer Name)
Zydelig
(Gilead Sciences, Inc)
Indication
The FDA has approved this product to be used in this manner.
(1) Relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities; and (2) Relapsed small lymphocytic lymphoma (SLL) in patients who have received at least two prior systemic therapies; and (3) Relapsed follicular B-cell non-Hodgkin lymphoma (FL) in patients who have received at least two prior systemic therapies.
More Information about this product Drug Information Portal